VNDA

Trichostatin A (VTR-297)

Relapsed or Refractory Hematologic Malignancies

Phase 1

Exp Date

TBD

Amp Volatility Score

Catalyst Info & Data Links

TITLE: Trichostatin A (VTR-297) for Relapsed or Refractory Hematologic Malignancies

  • ClinicalTrial.gov (NCT03838926): Tolerability Study of Trichostatin A In Subjects With Relapsed or Refractory Hematologic Malignancies

WHAT IS THE NEXT CATALYST EVENT?

  • TBD


WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?

  • TBD


PRIOR DATA

PRESS RELEASES


MECHANISM OF ACTION / RATIONALE

  • Acetylation and deacetylation of histones play an important role in transcription regulation of eukaryotic cells (Lehrmann et al., 2002; Mai et al., 2005). The acetylation status of histones and non-histone proteins is determined by histone deacetylases (HDACs) and histone acetyl-transferases (HATs). HATs add acetyl groups to lysine residues, while HDACs remove the acetyl groups. In general, acetylation of histone promotes a more relaxed chromatin structure, allowing transcriptional activation. HDACs can act as transcription repressors, due to histone deacetylation, and consequently promote chromatin condensation. HDAC inhibitors (HDACi) selectively alter gene transcription, in part, by chromatin remodeling and by changes in the structure of proteins in transcription factor complexes (Gui et al., 2004). Further, the HDACs have many non-histone proteins substrates such as hormone receptors, chaperone proteins and cytoskeleton proteins, which regulate cell proliferation and cell death (Table 1). Thus, HDACi-induced transformed cell death involves transcription-dependent and transcription-independent mechanisms (Learn more).

Updated by HC

#VNDA, #Trichostatin_A, #VTR-297, #Hematologic_Malignancies

Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

Recent Posts

See What The Community Is Saying - Click To See Full Post

Upcoming September 2020 COVID-...

Check out our AmpCards & #COVID19 catalyst tracker for investible small & mid-cap biopharma companies in the COVID therapeutics and vaccine race. Therapeutic candidate data from $VNDA, $BCRX, & $BSGM ...

VNDA - Interim Analysis from #...

#VNDA's interim analysis of the #ODYSSEY study demonstrated that hospitalized patients with #COVID-19 pneumonia improved sooner when treated with #tradipitant as compared to placebo. Summary of find...

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon